Purpose

Prospective, concurrently controlled, multi-center study to evaluate the safety and effectiveness of the Spinal Kinetics M6-C™ artificial cervical disc compared to anterior cervical discectomy and fusion (ACDF) for the treatment of contiguous two-level symptomatic cervical radiculopathy at vertebral levels from C3 to C7 with or without spinal cord compression.

Condition

Eligibility

Eligible Ages
Between 18 Years and 75 Years
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Diagnosis of degenerative cervical radiculopathy with or without spinal cord compression requiring surgical treatment at two contiguous levels from C3 to C7 demonstrated by signs and/or symptoms of disc herniation and/or osteophyte formation (e.g. neck and/or arm pain, radiculopathy, etc.) and is confirmed by patient history and radiographic studies (e.g. MRI, CT, x-rays, etc.) - Inadequate response to conservative medical care over a period of at least 6 weeks or have the presence of progressive symptoms or signs of nerve root/spinal cord compression in the face of continued non-operative management - Neck Disability Index score of ≥ 30% (raw score of ≥ 15/50) - Neck or arm pain Visual Analog Scale Score ≥ 4 on a scale of 0 to 10 - Willing and able to comply with the requirements of the protocol including follow-up requirements - Willing and able to sign a study specific informed consent - Skeletally mature and at least 18 years old but not older than 75 years old

Exclusion Criteria

  • More than two cervical levels requiring surgery, or two non-contiguous levels requiring surgery - Previous anterior cervical spine surgery - Axial neck pain as the solitary symptom - Previous posterior cervical spine surgery (such as a posterior element decompression) that destabilizes the cervical spine - Advanced cervical anatomical deformity (such as ankylosing spondylitis, scoliosis) at either of the operative levels or adjacent levels - Symptomatic facet arthrosis - Less than four degrees of motion in flexion/extension at either of the index levels - Instability as evidenced by subluxation greater than 3 millimeters at either of the index or adjacent levels as indicated on flexion/extension x-rays. - Advanced degenerative changes (e.g., spondylosis) at either of the index vertebral levels as evidenced by bridging osteophytes, central disc height less than 4 millimeters and/or < 50% of the adjacent normal intervertebral disc, or kyphotic deformity > 11 degrees on neutral x-rays - Severe cervical myelopathy (i.e., Nurick's Classification greater than 2) - Active systemic infection or infection at the operative site - Co-morbid medical conditions of the spine or upper extremities that may affect the cervical spine neurological and/or pain assessment - Metabolic bone disease such as osteoporosis that contradicts spinal surgery - History of an osteoporotic fracture of the spine, hip or wrist - History of an endocrine or metabolic disorder (e.g. Paget's disease) known to affect bone and mineral metabolism - Taking medications that may interfere with bony/soft tissue healing including chronic steroid use - Known allergy to titanium, stainless steels, polyurethane, polyethylene, or ethylene oxide residuals - Fibromyalgia, Rheumatoid Arthritis (or other autoimmune disease), or a systemic disorder such as HIV or acute hepatitis B or C. - Insulin dependent diabetes - Medical condition (e.g., unstable cardiac disease, cancer) that may result in patient death or have an effect on outcomes prior to study completion - Pregnant, or intend to become pregnant, during the course of the study - Severe obesity (Body Mass Index greater than 45) - Physical or mental condition (e.g. psychiatric disorder, senile dementia, Alzheimer's disease, alcohol or drug addiction) that would interfere with patient self-assessment of function, pain or quality of life. - Involved in current or pending spinal litigation where permanent disability benefits are being sought. - Incarcerated at time of study enrollment - Current participation in other investigational study.

Study Design

Phase
N/A
Study Type
Interventional
Allocation
Non-Randomized
Intervention Model
Parallel Assignment
Primary Purpose
Treatment
Masking
None (Open Label)
Masking Description
Participants will be assigned a treatment group by enrolling site and will not be blinded to the treatment group assignment before their surgery. Investigator, and site will not be blinded to treatment assignment due to the need to prepare for the respective surgery associated with the treatment assignment.

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
M6-C Artificial Cervical Disc
The M6-C is an investigational device composed of two outer and inner endplates made of titanium with a polycarbonate urethane nucleus (plastic center) and a polyethylene fiber annulus (strong thread-like binding). Around the polyethylene annulus is a polyurethane sheath (plastic cover). The outer endplates have keels to anchor the disc to bone. The outer endplates and keels are both coated with a titanium plasma spray. The M6-C is provided in two heights (6mm and 7mm) and four footprints (Medium, Medium Long, Large, Large Long).
  • Device: M6-C Artificial Cervical Disc
    An incision will be made in the front of the neck and the damaged disc located between cervical vertebrae (neck bones) will be removed so that the M6-C artificial cervical disc can be placed into the space where the damaged disc was removed. This procedure will be performed using x-ray technology (fluoroscopy) guide the surgeon in placement of the M6-C in between the cervical vertebrae. This process will be repeated to replace the second damaged disc.
Active Comparator
Anterior Cervical Discectomy & Fusion (ACDF)
ACDF will be performed using one of four FDA-approved anterior cervical plate systems and corticocancellous allograft bone. The four plating systems used in this study are: - Orthofix CETRA Anterior Cervical Plate System - Medtronic Sofamor/Danek Venture Anterior Cervical Plate System - DePuy Synthes: SKYLINE Anterior Cervical Plate System - Stryker Aviator Anterior Cervical Plating System
  • Device: ACDF
    One of four FDA-approved cervical plate systems will be used for the ACDF. An incision will be made in the front of the neck and the damaged disc located between cervical vertebrae (neck bones) will be removed. Then, a piece of donor bone will be placed in the space where the damaged disc was removed and a metal plate will be screwed into the bones above and below the disc. This procedure will be performed using x-ray technology (fluoroscopy) to guide the surgeon in the placement of the cervical plate system. This process will be repeated to treat the other damaged disc.

Recruiting Locations

Desert Institute for Spine Care
Phoenix, Arizona 85020
Contact:
Jennifer Camoriano
Jennifer@jehnresearch.com

Beverly Hills Spine Surgery
Beverly Hills, California 90210
Contact:
Nicole Phillips
310-385-7766
research@spinemd.com

Memorial Orthopaedic Surgical Group
Long Beach, California 90806
Contact:
Nanette Soto
nanettemsoto@gmail.com

Disc Sports & Spine Center
Newport Beach, California 92660
Contact:
Kaushal Bhatt, MD
949-988-7853
knbhatt@sccns.com

UC Irvine Medical Center
Orange, California 92868
Contact:
Brandon Lehman
bdlehman@hs.uci.edu

Institute of Neuro Innovation
Santa Monica, California 90404
Contact:
Jack Petros
research@inifoundation.org

St. Charles Spine Institute
Thousand Oaks, California 91860
Contact:
Kelly Olson, PA-C
805-379-2322
kelly@stcharlesspine.com

University of Colorado School of Medicine - Department of Orthopedics
Aurora, Colorado 80045
Contact:
Aubrie Nuccio
Aubrie.Nuccio@cuanschutz.edu

Steadman Philipon Research Institute
Vail, Colorado 81657
Contact:
Luz Thede
970-238-8103
lthede@sprivail.org

Orlando Health
Orlando, Florida 32809
Contact:
Charlene Carlo
321-841-1234
Charlene.Carlo@orlandohealth.com

Joseph Spine Institute
Tampa, Florida 33607
Contact:
Kim Nestor
813-570-8921
kim@researchtex.com

Longstreet Clinic
Gainesville, Georgia 30801
Contact:
Stacey May-Franklin
678-207-4231
Stacey.may@longstreetclinic.com

Axis Spine
Coeur d'Alene, Idaho 83815
Contact:
Elisa Maples, BS, CCRC
208-664-0290
Elisa.Maples@NWSH.com

Carle Health
Urbana, Illinois 61801
Contact:
Hope Carlson
217-383-3502
Hope.Carlson@carle.com

Brigham & Women's Hospital
Boston, Massachusetts 02115
Contact:
Jai Sandhu
8572962264
psandhu2@bwh.harvard.edu

Baystate Health
Springfield, Massachusetts 01199
Contact:
Jose Lugo
4137944367
Jose.Lugo@baystatehealth.org

Michigan Orthopedic Surgeons
Southfield, Michigan 48033
Contact:
Cameron Goldie
(248) 416-1243
cameron@researchtex.com

The Orthopedic Center of St. Louis
St. Louis, Missouri 63017
Contact:
Sarah Conners
sconners@spirittresearch.com

Metropolitan Neurosurgery Associates - Englewood Health
Englewood, New Jersey 07631
Contact:
Jennifer Snyder
jennifer.snyder@EHMCHealth.org

Upstate Medical University
East Syracuse, New York 13057
Contact:
Kayla Sweeney
sweenkay@upstate.edu

Mayfield Clinic
Cincinnati, Ohio 45209
Contact:
Lauren Murphy
513-569-5272
lmurphy@mayfieldclinic.com

St. David's Healthcare
Austin, Texas 78705
Contact:
Krishna Saini
512-544-8070
krishna.saini@stdavids.com

American Neurospine Institute/Medical City Frisco
Frisco, Texas 75033
Contact:
Ezioma Akwara
972-806-1188
info@americanneurospine.com

University of Utah Medical Center
Salt Lake City, Utah 84132
Contact:
Kirstianna Lombardi
801-585-9821
kirstianna.lombardi@utah.edu

More Details

NCT ID
NCT04982835
Status
Recruiting
Sponsor
Spinal Kinetics

Study Contact

Trai Curtis
214-937-3225
traiCurtis@orthofix.com

Detailed Description

Patients will be concurrently enrolled in the M6-C treatment group and the ACDF control group. Patients should have failed at least six weeks of conservative treatment or demonstrate progressive symptoms despite continued non-operative treatment. For the study, 263 patients will undergo either a two-level cervical artificial disc procedure, or an instrumented (ACDF) procedure as per site group assignment. Patients will be evaluated clinically, radiographically, and via the collection of patient-reported outcomes at 6 Weeks, 3 Months, 6 Months, 12 Months and 24 Months. The primary endpoint is Overall Success at 24 Months.

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.